TruSight Oncology IVD Solutions

One test. One report. One goal.

TruSight Oncology Comprehensive is an IVD test for comprehensive genomic profiling (CGP) based on DNA and RNA, consolidating multiple iterative tests into one. Using a single test for hundreds of current and emerging biomarkers, including a pan-cancer companion diagnostic, qualified healthcare professionals can access a clinically relevant report with actionable results to help redefine the journey for patients with cancer.

Learn how this IVD test can help guide personalized care decisions by maximizing actionable biomarker content in a single test to help drive better outcomes through precision medicine.

TruSight Oncology Comprehensive products

TruSight Oncology Comprehensive (EU)

CE-marked marked IVD kitted solution for comprehensive genomic profiling (CGP) for multiple solid tumor types.

View product details

TruSight Oncology Comprehensive (US)

FDA approved IVD kitted solution for comprehensive genomic profiling (CGP) for multiple solid tumor types.

View product details

Key features and benefits

Generate genomic profiles

Get mutational information on more than 500 genes to match patients with optimal therapeutic options. Detect DNA and RNA variants plus genomic signatures across multiple solid tumor types.

Help inform critical decisions

Test results help inform therapy decisions according to clinical guidelines. Content includes key biomarkers associated with drug labels, major clinical guideline recommendations, and clinical trials.

Offer in-house testing

Keep data in-house and avoid losing samples to send-out services. A streamlined four- to five-day sample-to-answer workflow helps serve more patients locally.

Conserve biopsy samples

Minimize risk of quantity not sufficient (QNS) issues by maximizing the genetic insights from each sample with comprehensive genomic coverage from a single test.

Consolidate multiple tests

Get comprehensive results in a single easy-to-interpret report, without waiting weeks for sequential results from separate tests. Leverage NGS to interrogate potential variants across different classes in a single test.

Maximize actionability

Obtain coverage of multiple variant classes in coding regions of cancer-related genes and genomic signatures. Stay ahead of expanding guidelines and new scientific literature with a comprehensive assay.

Key genes

Selection of key genes detected by TruSight Oncology Comprehensive includes:

PAN-CANCER GENES:

BRAF NTRK1 NTRK2 NTRK3 RET

Breast	AKT1	BRCA1	BRCA2	ERBB2	ESR1	PALB2	PIK3CA	PTEN
Colorectal	ERBB2	KRAS	NRAS
Bone	EGFR	ERG	ETV1	ETV4	EWSR1	FEV	FLI1	FUS	H3F3A	HEY1	IDH1
Bone	MDM2	NCOA2	SMARCB1
Lung	ALK	EGFR	ERBB2	KRAS	MET	NUTM1	ROS1
Melanoma	KIT	NRAS	ROS1
Ovarian	BRCA1	BRCA2	CTNNB1	ERBB2	FOXL2	TP53
CNS	ATRX	CDKN2A	CDKN2B	EGFR	H3F3A	HIST1H3C	IDH1	IDH2	MYCN	NF1	PTCH1
CNS	TERT	TP53
Prostate	ATM	ATR	BARD1	BRCA1	BRCA2	BRIP1	CDK12	CHEK1	CHEK2	FANCA	FANCL
Prostate	FGFR3	MLH1	MRE11	NBN	PALB2	PTEN	RAD51B	RAD51C	RAD51BD	RAD54L	TACC3
Thyroid	HRAS	KRAS	NRAS	TERT
Uterine	BRCA2	EPC1	ERBB2	ESR1	FOXO1	GREB1	JAZF1	NCOA2	NCOA3	NUTM2A	NUTM2B
Uterine	PAX3	PAX7	PHF1	POLE	SMARCA4	SUZ12	TP53	YWHAE

^*TruSight Oncology Comprehensive also contains many genes with biomarkers of potential clinical significance based on scientific literature evidence, presence in clinical trials, or linked to labels or guidelines in other histologies.¹ These genes are in addition to the genes with biomarkers of clinical significance linked to current drug labels or guidelines.

¹Content analysis provided by Velsara Knowledgebase v8.17, March 2024.

From sample to report in just 4-5 days

Implement a streamlined, IVD sample-to-answer solution, empowering you to generate accurate test results locally and improve the chances patients will be matched to targeted therapies or clinical trials.

^*Extraction kits must be purchased separately.

View sample TSO Comprehensive (EU) report

Pipeline of companion diagnostic indications under development

TruSight Oncology Comprehensive is indicated as a companion diagnostic test. See the product’s package insert for information on approved indications. Illumina has partnered with pharma companies to develop a growing pipeline of additional companion diagnostic indications.

The power of in-house CGP

Offer a turnaround time of 4-5 days versus multiple weeks for send-out testing
Automatically generate an intuitive report by leveraging integrated, on-board design
Streamline implementation efforts with validated IVD reagents
Maintain control of the original samples and data; reanalyze data when a new guideline, drug, or clinical trial becomes available
Improve access by offering tests at locations closer to the patient

Speak to a specialist

Contact an Illumina representative to learn more about the TruSight Oncology product line and find the right solutions for your needs.

Get in touch

TruSight Oncology IVD Solutions

TruSight Oncology Comprehensive IVD Solutions

Maximize actionable biomarker content

One test. One report. One goal.

TruSight Oncology Comprehensive products

TruSight Oncology Comprehensive (EU)

TruSight Oncology Comprehensive (US)

Key features and benefits

Generate genomic profiles

Help inform critical decisions

Offer in-house testing

Conserve biopsy samples

Consolidate multiple tests

Maximize actionability

Key genes

Selection of key genes detected by TruSight Oncology Comprehensive includes:

PAN-CANCER GENES:

BRAF NTRK1 NTRK2 NTRK3 RET

From sample to report in just 4-5 days

Pipeline of companion diagnostic indications under development

The power of in-house CGP

Resources

Precision medicine unlocked for all

Bring cancer into focus with CGP

CGP empowers broader access to precision oncology

Speak to a specialist

For every lab, everywhere

NextSeq 1000 and NextSeq 2000 Reagents

NGS Workflow Finder

DRAGEN v4.3 now available on-premises and on-cloud

Illumina Proactive Instrument Performance Service

Do more, faster than ever

Next-generation sequencing for beginners

Next-generation sequencing for beginners

Next-generation sequencing for beginners

Next-generation sequencing for beginners

Next-generation sequencing for beginners

Next-generation sequencing for beginners

Next-generation sequencing for beginners

This is the Genome Era

This is the Genome Era

This is the Genome Era

This is the Genome Era

This is the Genome Era

This is the Genome Era

This is the Genome Era

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

TruSight Oncology IVD Solutions

TruSight Oncology Comprehensive IVD Solutions

Maximize actionable biomarker content

One test. One report. One goal.

TruSight Oncology Comprehensive products

TruSight Oncology Comprehensive (EU)

TruSight Oncology Comprehensive (US)

Key features and benefits

Generate genomic profiles

Help inform critical decisions

Offer in-house testing

Conserve biopsy samples

Consolidate multiple tests

Maximize actionability

Key genes

Selection of key genes detected by TruSight Oncology Comprehensive includes:

PAN-CANCER GENES: